Introduction
Continuous ambulatory peritoneal dialysis (CAPD) was first described in 1976' and soon became a practical alternative to haemodialysis in patients with chronic renal failure.2 The clinical use of CAPD has grown rapidly since 1979 but is still regarded by many as an acceptable treatment for only a few patients, including the elderly and patients with diabetes. The main disadvantage of CAPD is peritonitis, which leads to a high drop out rate, though many centres in Europe have used CAPD for only high risk patients, and some centres treat small numbers of patients under conditions that are far from ideal. The European registry ofdialysis patients showed that up to 60% of patients starting CAPD transferred to another form of treatment within two years.34 The corresponding figure for haemodialysis is much lower and depends on the transplant rate. These figures do not amount to a controlled trial of CAPD v conventional haemodialysis; such a trial has not been performed and probably never will be.
There are several advantages associated with CAPD. It is simple to perform and requires no expensive equipment. Patients blood pressure, and bone disease are well controlled, and haemoglobin concentrations tend to be higher than in patients receiving haemodialysis.67 These reasons, coupled with limited facilities for haemodialysis, have ensured the rapid increase in use of CAPD in Newcastle from 1979 to 1983. We report results from Newcastle, as they represent a large study of CAPD as first line treatment for patients with chronic renal failure from a single centre.
Patients and methods
Two hundred and twenty nine consecutive patients (129 men) aged 3 months to 75 years (mean age 45) started receiving CAPD during the five years from January 1979 to December 1983. They were followed up for 12 to 65 months after starting treatment, having received CAPD for 0 5 to 62 (mean 19 8) months. This represents 378 patient years of experience of CAPD. Patients attended two hospitals-namely, the Royal Victoria Infirmary and Freeman Hospital, which together comprise the Newcastle renal unit.
All patients judged suitable for dialysis were treated, and this amounted to between 31 and 39 new patients/year/million population (catchment population 1 877 000) during the study. The proportion of new patients requiring renal replacement treatment who were treated by CAPD increased steadily over the first two years and remained at 60 -70% thereafter ( though complacency about this has been disturbed by recent measurements of bone aluminium concentrations. At the same time concern about metastatic calcification increased.' A quarter of all patients were receiving alfacalcidol at any one time (0-25-1 Fag daily), and there was no change in the proportion with increasing length of treatment with CAPD. Peritonitis was diagnosed when at least two of the following symptoms were present: pain, >50 white blood cells/ml of dialysate, and positive dialysate culture. The detailed management of peritonitis in this centre has been described previously."9 1
Patient survival and success of the technique were calculated with the actuarial method. " The patients who started receiving CAPD from January 1979 to December 1983 were treated as a cohort and followed until December 1984; the minimum follow up therefore was 12 months. All deaths were recorded, whether the patient was still receiving CAPD, had been transferred to haemodialysis, or had received a transplant. Such deaths were attributed to CAPD no matter for how long or short a period the patient received this form of treatment. Technique success was calculated in two ways, counting a successful transplant either as technique failure or as lost to follow up. Patients were considered to have stopped CAPD if there was an interruption of at least eight weeks, and the technique was considered to have failed in these patients. Stoppages of less than eight weeks-for example, due to hernia repair-were regarded as temporary interruptions and not as failures.
Fifty patients who had been treated predominantly by haemodialysis died between January 1980 and October 1985; their causes of death were determined retrospectively from the case notes. These patients had never had CAPD, but some had had short periods of intermittent peritoneal dialysis. Cardiovascular disease-Forty eight patients had evidence of pre-existing ischaemic heart disease (angina or previous myocardial infarction) when they started CAPD. Of these, 15 (310%) died compared with 31 (17%) of 181 patients who did not show evidence of pre-existing ischaemic heart disease and who died during follow up. Fifteen patients, including seven of the 48 with pre-existing disease, had a myocardial infarction during follow up that was fatal in eight cases. Of the 30 patients who had angina before starting dialysis, the symptoms improved or disappeared in 17, remained the same in 11, and worsened in only two during CAPD. Twelve of these patients subsequently died, nine of them from cardiovascular disease. Nine patients developed symptoms of angina de novo during CAPD. Seven patients had a history of stroke when they started CAPD, but none died or had a further stroke during follow up. Six fatal and two non-fatal strokes occurred in the rest of the population who received CAPD.
Penrtonitis-Five hundred and fifty five episodes of peritonitis, at a mean rate of one episode per 35 patient weeks, were recorded during the five years. The rate varied around the mean from year to year but showed no consistent trend towards improving on the first year's rate. Three hundred and ninety four episodes of infection (71%) were successfully cleared by one course of antibiotics. In 116 episodes (21%) the infection recurred after a course of antibiotics and was successfully cleared by a further course of treatment in 92, giving an overall successful outcome in 486 episodes (88%). In seven patients peritonitis led to obliteration of the peritoneal space, making it impossible to reinsert the catheter. The most common organism causing peritonitis was Staphylococcus epidermidis, which was isolated in 206 episodes (37%). Gram Discussion The increased use of CAPD has had an appreciable effect on the treatment of chronic renal failure in Newcastle. In the early years it allowed an expansion in the number of patients treated without an increase in facilities for haemodialysis. Some patients received successful transplants after receiving CAPD.'2 This period, however, has ended, and more facilities for haemodialysis are now needed if the number of transplants performed annually does not increase.
We have previously reported actuarial survival of patients receiving CAPD as being 94% at two years.7 That excellent result encouraged us to continue and expand our programme of CAPD, and it is therefore disappointing to see that this survival curve has not been maintained. There are several possible explanations. Firstly, in our previous reports we have counted as a death while receiving CAPD only those events that occurred while the patient was receiving that treatment or during an acute illness that began while CAPD was in progress. This gives an over optimistic picture of the procedure, as patients who are not doing well while receiving CAPD are transferred to haemodialysis, to which their subsequent deaths are attributed. Some authors have counted deaths during an arbitrary period-for example, three months-after a change of treatment as attributable to the first treatment. In this study we have analysed our data on the "intention to treat" principle. Patients who started CAPD were followed to the end of the study (December 1984 or earlier death), and all deaths were counted, whether they occurred during CAPD or subsequent treatments.
Secondly, it is an observed, though largely unexplained, fact that actuarial survival curves give an over optimistic forecast of eventual survival (Bradley BA, personal communication). As data accumulates the actuarial survival curve is increasingly based on patients who have passed the final point, so results usually deteriorate. Thirdly, our enthusiasm for CAPD led us to widen our indications and apply it to an increasingly disadvantaged population. This is shown by the increase in the mean age at the start of treatment during the study.
Despite this deterioration in our survival curve the results are similar to the European average survival for non-diabetic patients who started renal replacement treatment over the same period. At 941 36 months this varied from 84% for those aged 15-34 to 47% for those aged 65 years and over.4 They are better than the overall results from Europe in the same report. The Toronto group has continued to report an actuarial survival of 82% at two years,'3 14 and the United States registry reports a cumulative probability of dying while receiving CAPD of 26% at two years in 7404 patients.'5 These results cannot rival the best results ofhaemodialysis reported from a few centres with an actuarial survival ofover 90% at two years,'6 but they are similar to those expected from conventional haemodialysis schedules.4 '7 Cardiovascular disease remains the main cause of death in all reported groups of dialysis patients. On this evidence CAPD does not seem to exert a particularly detrimental effect on cardiovascular mortality or morbidity. Patients with pre-existing ischaemic heart disease do, however, have a worse outlook than those without, as expected. More worrying is the high incidence of death from abdominal complications, which, in most cases, are directly related to treatment with CAPD. The European registry has also suggested that abdominal causes of death, including complications not directly related to peritonitis such as perforated peptic ulcer, are increased in patients receiving CAPD. The incidence of deaths related to peritonitis has been much higher in other reports, however,'8 " and we have not seen lethal sclerosing peritonitis.
Efforts to reduce the mortality ofpatients receiving CAPD should therefore concentrate on the prevention of infection and early diagnosis of intra-abdominal catastrophe. Bazzato et al have reported excellent results in the prevention of infection with a double bag system,20 and many other systems are under trial. It seems sensible to remove infected catheters more readily. Our current policy is to remove the catheter if the infection has not responded to five days' treatment with an appropriate antibiotic, or if the infection recurs despite two courses of antibiotics. The infecting organism should also be taken into account. A fungal infection is rarely cured by antibiotics and is an indication for early removal. A Gram negative infection should alert the clinician to the possibility of bowel perforation.
This study emphasises the need for extensive back up haemodialysis and surgical facilities when runningaprogamme ofCAPD. Many patients require a temporary period on haemodialysis, and 35% to 45% ofpatients change their mode oftreatment or die within two years of starting CAPD. Despite treating half of the episodes of peritonitis at home inpatient beds are required for one to two weeks per patient year.
There is no absolute bar to long term treatment with CAPD; indeed, one of our patients has now been treated this way for more than six years. In our patients the incidence of failure of the peritoneal membrane has been low, and we have not seen sclerosing peritonitis in the absence of severe infection. The main limiting factor was peritonitis. The tendency of serum creatinine concentration to increase with increasing length of treatment with CAPD suggests that peritoneal function may decline slowly or that muscle mass increases with increased length of treatment with CAPD, though residual renal function presumably also declines and was not routinely measured in our patients. A cross sectional analysis of peritoneal function by a single hypertonic exchange in our patients suggested a decline in peritoneal clearance with time, predicting a 50%/o loss of function after an average of 13 years of being treated with CAPD.2" Although this observation needs to be confirmed by careful assessment over several years ofperitoneal function in many patients receiving CAPD, it suggests that loss of clearance is unlikely to be a problem in most patients awaiting a transplant. There is no evidence to suggest sequential loss of ultra-filtration during treatment with CAPD in our patients, though this has been recognised in other centres.2Y The true potential of the peritoneum will only be clear when effective methods of preventing infection have been developed.
We have previously reported that CAPD provides good control of secondary hyperparathyroidism.8 While this remains generally true it seems that CAPD cannot always reverse or hold established hyperparathyroidism in patients who have been treated for some time with some other mode of treatment.
What, then, is the present role of CAPD? Its use in children"3 or elderly24 or diabetic patients25 is not controversial, and our data suggest that it is also a reasonable option for young, fit patients ifit is used as a medium term measure before a transplant. 12 The increased use of CAPD has partly been related to its advantages over haemodialysis, particularly the general impression, now backed up by some studies, that the quality of life of patients receiving CAPD is better than that of those receiving haemodialysis.26N The short training period for CAPD compared with that required for home haemodialysis also makes it possible to accept more patients for treatment. These benefits must be weighed against the evidence that survival ofpatients receiving CAPD may be reduced compared with that in those receiving haemodialysis. Young patients unsuitable for receiving a transplant should be offered haemodialysis if it is available. Many units will continue to prefer haemodialysis as the safer option for most young patients, who for any reason must expect a long wait before receiving a transplant. If the average success in preventing peritonitis can be brought up to the best standards that have been reported, however, CAPD may be a reasonable long term treatment.
